| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) |
| Indication |
For the induction and maintenance of general anesthesia |
| Pharmacology |
Halothane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It reduces the blood pressure and frequently decreases the pulse rate and depresses respiration. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential. |
| Toxicity |
Toxic effects of halothane include malignant hyperthermia and hepatitis. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Halothane is metabolized in the liver, primarily by CYP2E1, and to a lesser extent by CYP3A4 and CYP2A6. |
| References |
| • |
Bovill JG: Inhalation anaesthesia: from diethyl ether to xenon. Handb Exp Pharmacol. 2008;(182):121-42.
[Pubmed]
|
|
| External Links |
|